Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 7Carcinoma 2Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Neoplasm Metastasis 1Glioma 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 55Carboplatin 50pembrolizumab 42Paclitaxel 42Gemcitabine 28Pemetrexed 23Radiotherapy 21Magnetic Resonance Spectroscopy 20Radiotherapy, Intensity-Modulated 18Docetaxel 17Cetuximab 17Specimen Handling 16Nivolumab 16Fluorouracil 16Cyclophosphamide 14durvalumab 13Bevacizumab 12Radiation 11130-nm albumin-bound paclitaxel 11Sorafenib 10Platinum 101,2-diaminocyclohexaneplatinum II citrate 10osimertinib 9Sunitinib 8Oxaliplatin 8Irinotecan 8Ipilimumab 8Everolimus 8Drug Therapy 8Capecitabine 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Carcinoma × futuximab × Clear all
NCT03549338 2020-09-28

Sym004 Versus Futuximab or Modotuximab in Patients With mCRC

Symphogen A/S

Phase 2 Terminated
2 enrolled 9 charts
Gastrointestinal

Carcinoma, Colorectal Neoplasms

NCT03717038 2019-02-04

Sym004 Versus TAS-102 in Patients With mCRC

Symphogen A/S

Phase 3 Withdrawn
Gastrointestinal

Carcinoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡